Inclusion Criteria:  All patients meeting the following criteria will be assessed for in the tumour board:  All lesions larger than 2cm pNET lesions with a size between 1.0 and 2.0 cm with growth (>1 mm/year) between sequential scans in follow-up Patients with in situ remaining 1.0 - 2.0 cm lesions after previous resection of a larger lesion.  All patients with an indication for surgery are considered eligible for participation in the PRIME study.  Exclusion Criteria:  Symptomatic pNET because of hormone production, with the exception of gastrinomas which are located in the submucosa of the duodenum concurrent treatment with a somatostatin analog concurrent treatment with chemotherapy peptide receptor radionuclide therapy in the past 12 months history of radiotherapy in the upper abdominal region MRI contraindications as per usual clinical care, such as claustrophobia and metal or electronic implants not compatible with MRI. Pregnancy (Other) metastatic disease WHO performance score 3-4